REG - Destiny Pharma PLC - XF Pipeline Update Meeting

Destiny PharmaAnnouncement

17/10/2023 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231017:nRSQ3009Qa&default-theme=true

RNS Number : 3009Q  Destiny Pharma PLC  17 October 2023

Destiny Pharma plc

 

("Destiny Pharma" or "the Company")

 

XF Pipeline Update Meeting with Leading Experts and New Microbiological Data
on XF-73

 

Brighton, United Kingdom - 17 October 2023 - Destiny Pharma plc (AIM:DEST),
a clinical stage biotechnology company focused on the development and
commercialisation of novel medicines to prevent life threatening infections,
confirms that it is hosting a meeting for analysts and investors on its XF
product pipeline later today at 2:00pm BST / 9:00am EDT.

 

The meeting will feature updates from Destiny Pharma leadership and
presentations from leading experts, as well as an interview with a UK patient.

 

Leadership updates will detail the commercial opportunity for XF-73 nasal,
including an analysis of the addressable market, and updates on the XF
platform, pipeline and potential, including new microbiological data
demonstrating the effectiveness of XF-73 against all known antibiotic strains
of Staphylococcus.

 

Leading experts will give the following presentations and discussions:

·     Professor Mark Wilcox, consultant microbiologist and head of
R&D in microbiology at the Leeds Teaching Hospital, and Richard Proctor,
Professor Emeritus of Medicine and Medical Microbiology and Immunology at the
University of Wisconsin-Madison, will present the issue of surgical site
infections and their impact on healthcare systems

·     Dr Alex Mericli, Associate Professor and Plastic Surgeon at MD
Anderson Cancer Center and Mr Raghbir Khakha, Consultant Trauma and
Orthopaedic Surgeon at Guy's and St Thomas's Hospital will present the reality
on the wards

 

The meeting will also include an interview with a UK patient who became
infected with Staph. aureus following surgery for a torn anterior cruciate
ligament.

 

Commenting on the event, Chris Tovey, Chief Executive Officer, Destiny Pharma,
said:

 

"The potential of XF-73 nasal is one of the reasons I was motivated to join
Destiny Pharma in its mission to reduce the emergence and impact of drug
resistant pathogens with preventative solutions.

 

"The innovative XF platform includes a blockbuster, $2bn plus opportunity in
the US alone, but has also shown utility beyond surgical site infections to
address fungal and dermal infections as well. Most  importantly, it has the
potential to play an essential role in protecting vulnerable patients, and in
doing so, save lives."

 

The meeting will be held in person at the offices of Cavendish, 1 Bartholomew
Close, London, EC1A 7BL, alongside the option of virtual attendance via the
Investor Meet platform. Prior registration for the event is required. To
attend in person please contact RD@destinypharma.com
(mailto:RD@destinypharma.com) .

 

 

For further information, please contact:

 

Destiny Pharma plc

Chris Tovey, CEO

Shaun Claydon, CFO

+44 (0) 127 370 4440

pressoffice@destinypharma.com (mailto:pressoffice@destinypharma.com)

 

Powerscourt Group

Sarah Macleod / Adam Michael / Ollie Simmonds / Christopher Ward

+44 (0) 20 7250 1446

Destiny@powerscourt-group.com (mailto:Destiny@powerscourt-group.com)

 

Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)

Geoff Nash / George Dollemore, Corporate Finance

Nigel Birks / Harriet Ward, ECM

+44 (0) 207 220 0500

 

Shore Capital (Joint Broker)

Daniel Bush / James Thomas / Lucy Bowden

+44 (0) 207 408 4090

 

 

About Destiny Pharma

 

Destiny Pharma is an innovative, clinical-stage biotechnology company focused
on the development and commercialisation of novel medicines that can prevent
life-threatening infections. The company's drug development pipeline includes
two late stage assets NTCD-M3, a microbiome-based biotherapeutic for the
prevention of C. difficile infection (CDI) recurrence which is the leading
cause of hospital acquired infection in the US, and XF-73 nasal gel, a
proprietary drug targeting the prevention of post-surgical staphylococcal
hospital infections including MRSA.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCBQLLFXBLBFBQ